Critics: Designer baby patent 'a serious mistake'

The company counters the testing is just a fun way for parents to find out about their child's possible traits.

LOS ANGELES TIMESOctober 5, 2013 

LOS ANGELES - What's even more repulsive than the idea of using DNA tests to help people create designer babies? Getting a patent for the idea.

23andMe, the pioneering direct-to-consumer genetic testing company, was awarded such a patent in September. U.S. Patent No. 8,543,339 is titled "Gamete donor selection based on genetic calculations," and among the inventions it claims is the idea of using genetic tests and computer programs to predict the likely traits of a baby based on the DNA of its parents.

Needless to say, this patent does not sit well with bioethicists. In a commentary published Thursday in the journal Genetics in Medicine, a group of bioethicists in Europe describes another scenario covered by the patent: prospective parents seeking egg and sperm donors with specific DNA variants to maximize their chance of having a child who will grow to a specific height, or develop the slow-twitch muscles that make someone a better endurance athlete, or have certain personality characteristics. Some traits, such as gender and eye color, could be chosen pretty reliably.

The Center for Genetics and Society, a bioethics think-tank based in Berkeley, Calif., has called on 23andMe "to abstain from developing or offering any product or service based on this patent, and to use its patent to prevent others from doing so."

'ETHICALLY TREACHEROUS'

"We believe the patent office made a serious mistake in allowing a patent that includes drop-down menus from which to choose a future child's traits," Marcy Darnovsky, the center's executive director, said in a statement.

Any such system would be "ethically and socially treacherous," she said. "It could encourage the dangerous idea that science should be used to breed 'better' people, breathing new life into the specter of eugenics that has long hung over the field of genetics."

For its part, 23andMe says it has no plans to offer the sort of designer-baby service that critics are worried about. Speaking on the company's behalf, blogger "ScottH" wrote that the Mountain View, Calif., company intended to patent the technology behind its Family Traits Inheritance Calculator, which "is used by our customers as a fun way to look at such things as what eye color their child might have or if their child will be able to perceive bitter taste or be lactose intolerant."

PATENT DEBATE

But five years ago, when the patent application was filed, the company thought "the technology could have potential applications for fertility clinics so language specific to the fertility treatment process was included in the patent," ScottH wrote. As it turned out, the company never pursued that line of business, "nor do we have any plans to do so," he wrote.

Even if 23andMe never brings a design-your-own-baby DNA test to market - and even if it uses its patent to prevent anyone else from doing so - the authors of the Genetics in Medicine report say it's still troubling that the U.S. Patent and Trademark Office would award this patent in the first place.

"At no stage during the examination of the patent application did the patent office examiner question whether techniques for facilitating the 'design' of future human babies were appropriate subject matter for a patent," they wrote.

In June, the U.S. Supreme Court ruled that individual genes were products of nature, not inventions, and thus could not be patented by companies.

Idaho Statesman is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Commenting FAQs | Terms of Service